Renaissance Technologies LLC Buys Shares of 82,900 Delcath Systems, Inc. (NASDAQ:DCTH)

Renaissance Technologies LLC bought a new position in Delcath Systems, Inc. (NASDAQ:DCTH - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 82,900 shares of the company's stock, valued at approximately $694,000. Renaissance Technologies LLC owned 0.30% of Delcath Systems as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the company. AIGH Capital Management LLC increased its position in Delcath Systems by 1.7% during the 2nd quarter. AIGH Capital Management LLC now owns 2,399,792 shares of the company's stock valued at $20,086,000 after purchasing an additional 40,064 shares during the period. Legato Capital Management LLC purchased a new position in Delcath Systems during the 2nd quarter valued at $966,000. Rosalind Advisors Inc. increased its position in Delcath Systems by 155.1% during the 2nd quarter. Rosalind Advisors Inc. now owns 2,650,389 shares of the company's stock valued at $22,184,000 after purchasing an additional 1,611,561 shares during the period. Levin Capital Strategies L.P. increased its position in Delcath Systems by 12.2% during the 1st quarter. Levin Capital Strategies L.P. now owns 54,969 shares of the company's stock valued at $262,000 after purchasing an additional 5,969 shares during the period. Finally, BVF Inc. IL increased its position in Delcath Systems by 23.1% during the 1st quarter. BVF Inc. IL now owns 1,202,067 shares of the company's stock valued at $5,734,000 after purchasing an additional 225,918 shares during the period. 61.12% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on DCTH shares. Stephens reissued an "overweight" rating and set a $25.00 price objective on shares of Delcath Systems in a research report on Tuesday, August 6th. Craig Hallum began coverage on shares of Delcath Systems in a research report on Friday, June 28th. They issued a "buy" rating and a $18.00 target price on the stock. StockNews.com raised shares of Delcath Systems from a "sell" rating to a "hold" rating in a research report on Friday, September 27th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $22.00 target price on shares of Delcath Systems in a research report on Tuesday, August 6th.

Delcath Systems Stock Up 0.8 %

Shares of NASDAQ:DCTH traded up $0.07 during midday trading on Wednesday, reaching $8.51. The company's stock had a trading volume of 154,713 shares, compared to its average volume of 254,059. The firm has a market capitalization of $236.46 million, a P/E ratio of -3.22 and a beta of 0.78. The firm has a 50 day moving average of $8.94 and a 200-day moving average of $7.50. Delcath Systems, Inc. has a 12-month low of $2.25 and a 12-month high of $11.74.

Delcath Systems (NASDAQ:DCTH - Get Free Report) last announced its quarterly earnings results on Monday, August 5th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.12). The firm had revenue of $7.77 million during the quarter, compared to the consensus estimate of $5.00 million. Delcath Systems had a negative return on equity of 312.48% and a negative net margin of 474.22%. During the same quarter in the previous year, the firm earned ($0.58) EPS. On average, research analysts predict that Delcath Systems, Inc. will post -1.67 EPS for the current year.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.